Navigation Links
MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition
Date:11/16/2009

GAITHERSBURG, Md., Nov. 16 /PRNewswire/ -- MedImmune today announced the winners of a research abstract competition highlighting the work of the next generation of scientific leaders in respiratory disease, inflammation and autoimmunity (RIA). Students and postdoctoral fellows from across the country were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, a leading biologics company headquartered in Gaithersburg, Maryland.

The competition's ten finalists convened today at the company's headquarters to present their research to an expert panel of MedImmune judges. The three winners were announced at the awards ceremony following the presentations.

First prize of $2,000 was awarded to Eric Boilard, a postdoctoral student of Harvard Medical School and Brigham & Women's Hospital for his research on the role of platelets in amplifying inflammation in arthritis. "I would like to thank everyone at MedImmune for sponsoring this competition. I am honored to be a winner and grateful for the opportunity to receive such great feedback from renowned individuals on the panel."

Second and third prizes of $1,000 and $500 were awarded to Irving Allen of University of North Carolina and Kerstin Kiefer of Boston University School of Medicine, respectively.

"We saw some very high-caliber preclinical approaches," said Anthony J. Coyle, Ph.D., vice president, research and development and head, respiratory, inflammation and autoimmunity research at MedImmune. "Their research could pave the way for further understanding of the mechanism of these diseases, and could potentially help in the development of new therapies."

"We are committed to investing in future scientists and promoting health and science education," said Bahija Jallal, Senior Vice President of Research and Development at MedImmune. "We were impressed with today's presentations, and congratulate all of the ten finalists on their thought-provoking work."

The competition was open to graduate students and postdoctoral fellows worldwide. The expert panel of judges evaluated the abstracts according to the following criteria: scientific rationale, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

Notes to Editors:

    First Place:      Harvard Medical School, Brigham & Women's Hospital
                      postdoctoral student Eric Boilard. The title of his
                      abstract is "Platelets amplify inflammation in arthritis
                      via collagen-dependent microparticle production."

    Second Place:     University of North Carolina at Chapel Hill postdoctoral
                      student Irving Allen. The title of his abstract is
                      "NLRX1 is a regulator of the innate immune response to
                      influenza A virus infection."

    Third Place:      Boston University School of Medicine postdoctoral
                      student Kerstin Kiefer. The title of her abstract is
                      "The role of TAM receptor tyrosine kinases in B cell
                      activation and differentiation."

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

Media Contact:

    Perla Copernik
    (301) 398-4952

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. MedImmune Expands Scientific and Engineering Leadership
8. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
9. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
10. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
11. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology: